We are live on
!
Find out more
BCB
Brian C. Broderick Portfolio holdings
AUM
$646M
1-Year Est. Return
43.3%
This Fund
S&P 500
This Quarter
Est. Return
+10.71%
1 Year Est. Return
+43.3%
3 Year Est. Return
+98.62%
5 Year Est. Return
+125.42%
10 Year Est. Return
+408.39%
AUM
$416M
AUM Growth
+$41.2M
(+11%)
Cap. Flow
+$4.7M
Cap. Flow
% of AUM
1.13%
Top 10 Holdings %
Top 10 Hldgs %
39.12%
Holding
82
New
2
Increased
36
Reduced
23
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edwards Lifesciences
EW
|
+$1.71M |
| 2 |
Aptiv
APTV
|
+$1.34M |
| 3 |
Nike
NKE
|
+$1.23M |
| 4 |
TJX Companies
TJX
|
+$990K |
| 5 |
Amazon
AMZN
|
+$989K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Novartis
NVS
|
+$2.27M |
| 2 |
Chubb
CB
|
+$1.94M |
| 3 |
Intel
INTC
|
+$858K |
| 4 |
Cisco
CSCO
|
+$830K |
| 5 |
Danaher
DHR
|
+$658K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 24.62% |
| 2 | Healthcare | 21.79% |
| 3 | Industrials | 12.84% |
| 4 | Miscellaneous | 12.05% |
| 5 | Consumer Discretionary | 8.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Coca-Cola
KO
$379B
| $431K | 0.1% |
7,280
-4,100
| -36% | -$228K |
|
52
Merck
MRK
$371B
| $431K | 0.1% |
5,615
-3,468
| -38% | -$276K |
|
53
Pfizer
PFE
$162B
| $422K | 0.1% |
7,154
| – | – |
|
54
NextEra Energy
NEE
$174B
| $355K | 0.09% |
3,800
| – | – |
|
55
McCormick & Company Non-Voting
MKC
$14B
| $354K | 0.09% |
+3,660
| New | +$312K |
|
56
Deere & Co
DE
$187B
| $312K | 0.08% |
910
| – | – |
|
57
IBM
IBM
$221B
| $308K | 0.07% |
2,297
+417
| +22% | +$52.3K |
|
58
ConocoPhillips
COP
$161B
| $295K | 0.07% |
4,084
| – | – |
|
59
McDonald's
MCD
$181B
| $295K | 0.07% |
1,100
| – | – |
|
60
CSX Corp
CSX
$91.5B
| $293K | 0.07% |
7,800
| – | – |
|
61
Ingersoll Rand
IR
$29.6B
| $271K | 0.07% |
4,385
| – | – |
|
62
General Mills
GIS
$20.5B
| $269K | 0.06% |
4,000
| – | – |
|
63
Walmart Inc
WMT
$850B
| $225K | 0.05% |
4,650
| – | – |
|
64
J.M. Smucker
SJM
$13.5B
| $217K | 0.05% |
+1,600
| New | +$204K |
|
65
GE Aerospace
GE
$350B
| $215K | 0.05% |
3,660
-1,805
| -33% | -$113K |
|
66
Baxter International
BAX
$13.4B
| – | – |
-3,600
| Closed | -$290K |
|
|
67
Chubb
CB
$132B
| – | – |
-11,190
| Closed | -$1.94M |
|
68
Cigna
CI
$74.7B
| – | – |
-1,948
| Closed | -$390K |
|
69
Cyclerion Therapeutics
CYCN
$19.9M
| – | – |
-1,609
| Closed | -$99K |
|
70
Denali Therapeutics
DNLI
$3.56B
| – | – |
-4,000
| Closed | -$202K |
|
71
Dow Inc
DOW
$21.3B
| – | – |
-3,822
| Closed | -$219K |
|
72
Eli Lilly
LLY
$1.02T
| – | – |
-1,307
| Closed | -$303K |
|
Similar funds
JCP
CAMV
LFS
AP
PSC
WW
HIS
GF
Brian C. Broderick's Q4 2021 Portfolio in Review
As of Q4 2021, Brian C. Broderick held 82 positions worth $416M, up 11% from $375M the previous quarter. Its ten largest holdings account for 39% of the portfolio.
Brian C. Broderick's Q4 2021 filing shows 2 new, 36 increased, 23 reduced and 8 closed positions. Its largest new stake was McCormick & Company Non-Voting: 3,660 shares worth $354K. The largest sale was Novartis, an estimated $2.27M.
By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 23% a quarter earlier, followed by Healthcare and Industrials.
- Brian C. Broderick's largest Q4 2021 buy was McCormick & Company Non-Voting: 3,660 shares worth $354K.
- Brian C. Broderick added most to Edwards Lifesciences in Q4 2021, an estimated $1.71M increase.
- Brian C. Broderick's biggest Q4 2021 reduction was Novartis, cutting an estimated $2.27M.
- Brian C. Broderick fully exited Chubb in Q4 2021, selling an estimated $1.94M.
- Brian C. Broderick's ten largest holdings make up 39% of its $416M portfolio in Q4 2021.
- Brian C. Broderick opened 2 new positions and closed 8 in Q4 2021.
- Brian C. Broderick's portfolio value rose 11% quarter-over-quarter to $416M.
Based on Brian C. Broderick's 13F filing for Q4 2021, filed 8 Feb 2022.